← Back to Search

MEK Inhibitor

Treatment for Bladder Cancer

N/A
Waitlist Available
Research Sponsored by xCures
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Summary

The objective of this expanded access program is to provide ulixertinib (BVD-523) for compassionate use in advanced cancer patients with MAPK pathway-altered solid tumor(s), including but not limited to KRAS, NRAS, HRAS, BRAF, MEK, and ERK mutations who have incomplete response to or have exhausted available therapies. Ulixertinib is available for treatment as monotherapy or in combination with other clinically tolerable agent(s), conditionally approved by the drug manufacturer.

Eligible Conditions
  • Bladder Cancer
  • Head and Neck Cancers
  • Stomach Cancer
  • Esophageal Cancer
  • Bile Duct Cancer
  • Ovarian Cancer
  • Liver Cancer
  • Glioblastoma
  • MAPK Gene Mutation
  • KRAS Mutation
  • BRAF Gene Mutation
  • Neurofibromatosis
  • Gene Mutation
  • MAP2K1
  • ERK Mutation
  • Pancreatic Cancer
  • Small Bowel Cancer
  • Colorectal Cancer
  • Melanoma
  • Non-Small Cell Lung Cancer
  • Thyroid Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Find a Location

Who is running the clinical trial?

xCuresLead Sponsor
6 Previous Clinical Trials
15,602 Total Patients Enrolled
Cancer CommonsOTHER
2 Previous Clinical Trials
15,000 Total Patients Enrolled
~233 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top